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Abstract: Psoriasis is one of the most common skin diseases. The mainstay of treatment for the 
vast majority of patients is topical therapy. A rising ﬁ  rst-line treatment modality for psoriasis 
vulgaris is the two-compound ointment containing calcipotriol 50 µg/g plus betamethasone 
dipropionate 0.5 mg/g (Dovobet®, Daivobet®, Taclonex®), which combines a vitamin D analog 
and a corticosteroid. This innovative formulation preserves the activity and bioavailability of 
the two components and many clinical studies have demonstrated that it has a greater efﬁ  cacy, 
tolerability, and a rapid onset of action compared with its individual ingredients or tacalcitol.
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Introduction
Psoriasis is a chronic inﬂ  ammatory skin disease with increased epidermal proliferation. 
Psoriasis vulgaris, the most common form of psoriasis, is usually characterized by 
well-circumscribed, red, raised, scaly plagues. Lesions usually occur symmetrically, 
affecting the knees, elbows, buttocks, scalp, extremities and areas subjected to 
trauma (Gottlieb 1998). The prevalence of psoriasis is generally estimated at between 
0.5%–4.6% of the global population with rates varying among countries (Plunkett 
and Marks 1998; Koo 1999; Christophers 2001; Lebwohl 2003; Getland et al 2005). 
By combining age of onset and human leukocyte antigen pattern, two subtypes of 
psoriasis have been described: Type I with early onset ( 30 years of age) and familial 
inheritance; Type II psoriasis is usually a milder disease starting at age 55–60 years 
with no genetic predisposition (Swanbeck et al 1995).
Psoriasis has a signiﬁ  cant impact on patient quality of life. The social and 
psychological impact is considerable. Psoriasis is not considered a life-threatening 
disease, but it is well established that those patients may experience a range of 
psychosocial difﬁ  culties, including elevated levels of anxiety, depression, and worry 
(Richards and Fortune 2006).
The histopathology is characterized by increased rate of epidermal proliferation 
with impaired differentiation of keratinocytes. Dermal blood vessels are dilated and 
there is inﬁ  ltration of the skin with immunologically active cells (Bos 1988).
The etiopathogenesis of psoriasis is still not fully understood and involves a 
complex interaction of genetic and environmental factors. Psoriasis was originally 
thought to be a keratinisation disorder, but now substantial evidence indicates that 
different components of the innate- and acquired-immunity (T cells, dendritic cells, 
and inﬂ  ammatory cytokines) are critically involved in initiating and maintaining the 
inﬂ  ammatory response (Tagami and Alba 1997; Jullien 2006).
Topical therapy is the mainstay of treatment for mild to moderate psoriasis and 
often the initial treatment for severe psoriasis (Ashcroft et al 2000). About 80% of 
patients with psoriasis are treated topically (Peeters et al 2005). Patients treated with Therapeutics and Clinical Risk Management 2008:4(1) 142
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phototherapy or systemic agents, including biological agents, 
can also be managed with topical agents as adjunctive therapy 
(Guenther et al 2004).
Topical corticosteroids and vitamin D3 analogue are the 
treatment of choice (van de Karkhof and Vissers 2003). 
Combination therapy is known to be superior to monotherapy 
and is commonly used. By combining medications with a 
different mechanism of action and safety proﬁ  le, efﬁ  cacy 
can be enhanced and/or safety improved. A calcipotriol/
betamethasone dipropionate two-compound ointment 
(Dovobet®, Daivobet®, Taclonex®, LEO Pharma A/S 
Ballerup, Denmark) has been shown to be safe and effective 
in the treatment of psoriasis vulgaris.
Chemical properties, 
pharmacodynamics, 
and pharmacokinetics 
of calcipotriol/betamethasone 
dipropionate
Calcipotriol (Daivonex®, Dovonex®), a synthetic analog of 
1,25-dixydroxyvitamin D3, binds to the vitamin D receptor and 
act as a heterodimer with the retinoid X receptor (RXR) (Bury 
et al 2001). Vitamin D receptors are present on keratinocytes 
and lymphocytes. The epidermal hyperproliferation, abnormal 
keratinization, and angiogenesis seen in psoriasis are normalized 
with vitamin D analogs; apoptosis is induced in inﬂ  ammatory 
cells and there is a switch from Th1 cytokines to Th2 cytokines 
(van de Kerkhof 1995, 1998; Barna et al 1997). To be more 
speciﬁ  c, calcipotriol can modulate the inﬂ  ammatory process 
in psoriasis by decreasing the levels of interleukin-1 (IL-1) 
(Muller et al 1988) and IL-6 (Muller et al 1991) and by reducing 
the CD45RO and C8+ T cells. Morover, it increases the levels 
of transforming growth factor-β1 (TGF-β1) and -β2, which 
inhibit the epithelial cell growth (Koli and Keski-Oja 1993). 
Calcipotriol is sensitive to oxidizing agents and acidic residues; 
it reacts with alcohols, and easily undergoes epimerisation 
processes (Charakida et al 2006). Twice-daily calcipotriol has 
an excellent safety proﬁ  le (Cullen 1996) and is more efﬁ  cacious 
than short-contact anthralin (Berth-Jones et al 1992), tar (Tham 
et al 1994), ﬂ  uocinonide ointment (Bruce et al 1994) and is at 
least as efﬁ  cacious as betamethasone 17-valerate 0.1% ointment 
(Kragballe et al 1991; Cunliffe et al 1992). Despite its side-
effect of local irritation, calcipotriol is not associated with the 
cutaneous atrophy of topical corticosteroids or messiness of 
tar and anthralin.
Betamethasone dipropionate is a class III potency, 
synthetic, fluorinated topical steroid (World Health 
Organization classification). Betamethasone binds to 
cytoplasmic glucocorticoid receptors and then is rapidly 
translocated to the nucleus where it stimulates or inhibits 
the genes regulating inﬂ  ammation (Wissink et al 1998). 
Corticosteroids improve several markers of inﬂ  ammation 
(infiltrate, erythema, edema, and hyperproliferation) in 
psoriasis vulgaris without affecting terminal differentiation 
(Fenlon and Plosker 2004).They also inhibit production of 
cytokines (IL-1, IL-6, IL-8, tumor necrosis factor-α, inter-
feron-γ), reduce mediators of inﬂ  ammation (prostaglandins, 
leukotrienes, nitric oxide), decrease the abnormal CD4:CD8 
ratio and the number and activity of Langerhans’ cells (Beato 
1989; De Jong et al 1995; Vissers et al 2004).
Corticosteroids are stable under acidic conditions, but 
sensitive to alkaline residues and oxidizing agents. If water 
is present in the formulation, calcipotriol requires a relatively 
high pH ( 8) for maximum stability, whereas betametha-
sone dipropionate requires pH-values in the range of 4–6 
(Simonsen et al 2004). Calcipotriol and topical steroids are 
difﬁ  cult to mix in the same single formulation because they 
inactivate each other.
In their study, Simonsen and colleagues (2004) dem-
onstrated that it is possible to combine the two otherwise 
incompatible drug substances in a formulation by care-
ful selection of the vehicle components. This new two-
compound ointment (Dovobet®, Daivobet®, Taclonex®, LEO 
Pharma A/S Ballerup, Denmark) is a combination of calci-
potriol 50 µg/g and betamethasone dipropionate 0.5 mg/g 
in a single vehicle (5% polyoxypropylene-15-stearyl ether) 
achieving optimal delivery of both drugs in an active state 
into the skin (Simonsen et al 2004), without affecting each 
other’s absorption (Hansen 2001; Guenther 2005) and it is 
stable and active for more than 2 years at room temperature 
(Traulsen 2004).
The combination of calcipotriol with a corticosteroid 
improves efﬁ  cacy and decreases skin irritation. Two stud-
ies showed that the administration of the combination of 
calcipotriol and betamethasone dipropionate for a 4-week 
period improved keratinocyte proliferation, differentiation 
(Van Rossum et al 2001; Vissers et al 2004), and inﬂ  amma-
tory characteristics (Van Rossum et al 2001). Also this new 
two-compound ointment induces a steroid-sparing effect in 
long-term treatments and thereby reduces the risk of skin atro-
phy and skin thickness (Traulsen et al 2003), stretch marks, 
telangiectasia, rebound phenomenon, and tachyphylaxis. 
Tachyphylaxis is a clinical concern, but it was not reported 
in the clinical studies. The intermittent use of corticosteroid 
or the use of a potent antipsoriatic agent (calcipotriol) may Therapeutics and Clinical Risk Management 2008:4(1) 143
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possibly be attributable to prevention or minimization of 
tachyphylaxis (Singh et al 2000). A steroid-sparing effect and 
the improvement of patient compliance are expected with a 
once-daily treatment regimen and the faster onset of action. 
Last, but not least, the systemic absorption of calcipotriol and 
betamethasone dipropionate from the combination product 
through normal skin is less than 1%.
Clinical efﬁ  cacy
To date, six large phase III international, multicenter, 
prospective, randomized, blinded, clinical studies with the 
two-compound ointment have been performed, including 
more than 6000 patients with psoriasis vulgaris (Douglas 
et al 2002; Guenther et al 2002; Kaufman et al 2002; Papp 
et al 2003; Kragballe et al 2004; Ortonne et al 2004). These 
studies have shown that after 4 weeks of treatment, the mean 
reduction of Psoriasis Area and Severity Index (PASI) ranged 
from 65%–74.4% with the two-compound ointment applied 
once or twice daily (Kragballe and van de Kerkhof 2006), 
while calcipotriol, tacalcitol, or betamethasone dipropionate 
alone produced a mean reduction of PASI ranging from 46% 
to 59%, 33.3%, and from 57% to 63%, respectively. In a 
study where the two-compound ointment was applied once 
daily for 8 weeks, the maximum treatment effect was noted 
after 5 weeks and was maintained throughout the 8-week 
treatment period (Kragballe et al 2004).
Patient demographics were similar in all six studies:
•  Mean age: 48 years
•  Male (%): 53.8–69.6 (mean 60%)
•  Baseline PASI: 9.7–10.9 (mean 10)
•  Duration of psoriasis (years): 18.3–20.2 (mean 19 
years)
The six studies (Table 1) were designed to compare 
uses of the two-compound ointments (Kragballe and van de 
Kerkhof 2006):
•  Study 1: the two-compound ointment was applied twice 
daily, with each of the active ingredients applied twice 
daily alone in the new vehicle (Papp et al 2003)
•  Study 2: the two-compound ointment was applied twice 
daily, with each of the active ingredients applied twice 
daily in their marketed ointment formulation (Douglas 
et al 2002)
•  Study 3: the two-compound ointment was applied once 
or twice daily, with calcipotriol ointment applied twice 
daily (Guenther et al 2002)
•  Study 4: the two-compound ointment was applied once 
daily, with each of the active ingredients applied once 
daily alone in the new vehicle (Kaufmann et al 2002)
•  Study 5: the two-compound ointment was applied once 
daily for 8 weeks followed by calcipotriol once daily for 
4 weeks, with a) the two compound ointment applied 
once daily for 4 weeks followed by 8 weeks of treat-
ment with calcipotriol once daily on weekdays and the 
two-compound product once daily at weekends and b) 
calcipotriol ointment twice daily for 12 weeks (Kragballe 
et al 2004)
•  Study 6: the two-compound ointment was applied 
once daily, with tacalcitol ointment applied once daily 
(Ortonne et al 2004)
It is clearly demonstrated by these studies that the two-
compound ointment of calcipotriol/betamethasone dipropio-
nate applied once daily is more effective than either agent 
alone or tacalcitol; it has a more rapid onset of action and 
this effect is sustained. These advantages are not affected by 
age (Parslew and Traulsen 2005), sex, or baseline disease 
severity (van de Kerkhof et al 2005; Anstey and Kragballe 
2006). Anstey and Kragballe (2006) conducted a very 
interesting study.
Table 1  Comparision of studies on the treatment of psoriasis 
vulgaris with two-compound ointment
Study 1 Papp et al 2003 Two-compound ointment applied 
twice daily, with each of the active 
ingredients applied twice daily alone 
in the new vehicle
Study 2 Douglas et al 2002 Two-compound ointment applied 
twice daily, with each of the active 
ingredients applied twice daily with 
their marketed ointment formulation
Study 3 Guenther et al 2002 Two-compound ointment applied 
once or twice daily, with calcipotriol 
ointment applied twice daily
Study 4 Kaufmann et al 2002 Two-compound ointment applied 
once daily, with each of the active 
ingredients applied once daily alone in 
the new vehicle
Study 5 Kragballe et al 2004 1. Two compound ointment applied 
once daily for 8 weeks followed by 
calcipotriol once daily for 4 weeks
2. Daily use for 4 weeks followed by 
8 weeks of treatment with calcipot-
riol once daily on weekdays and the 
two-compound product once daily at 
weekends and
3. Calcipotriol ointment twice daily 
for 12 weeks
Study 6 Ortonne et al 2004 1. The two-compound ointment 
applied once daily, with
2. Tacalcitol ointment applied once 
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Results from these six phase III studies for the 
two-compound ointment were pooled and the PASI 50 and 
PASI 75 response rates were calculated for patients with 
severe (PASI   17) or less severe psoriasis (PASI   17) at 
baseline. Results from phase III studies using the biological 
agents efalizumab, etanercept, or alefacept were also pooled. 
In patients with severe psoriasis, the PASI 50 response rate 
was 88.8% after 4 weeks of treatment with the two-compound 
ointment, 69.2% with betamethasone dipropionate, 53.8% 
with calcipotriol, and 30% with ointment vehicle. The PASI 
75 response rate in patients with severe psoriasis was 54.1% 
treated with the two-compound ointment for 4 weeks, 32.7% 
of patients treated with betamethasone dipropionate, and 
20% of calcipotriol-treated patients. The number of patients 
achieving PASI 50 and PASI 75 after 12 weeks of treat-
ment with biologicals was 56% and 28% for alefacept, 59% 
and 27% for efalizumab, and 74% and 49% for etanercept, 
respectively. Indirect comparisons across studies should 
be interpreted with caution (Antsey and Kragballe 2006). 
Nevertheless, it is important to point out the efﬁ  cacy and 
the rapid onset of action of a topical treatment in patients 
with severe disease. Further clinical trials comparing the 
effectiveness between biological and topical therapies for 
psoriasis must be conducted to determine the treatment of 
choice for severe psoriasis.
Another study from van de Kerkhof (2004) assessed 
the impact of treatment with the two-compound ointment 
on patient quality of life (QoL). A statistically signiﬁ  cant 
positive effect on patient QoL was noted, which reﬂ  ects the 
superior efﬁ  cacy of calcipotriol/betamethasone dipropionate 
ointment and the advantage of once-daily application.
A randomized parallel-group clinical trial was designed 
to investigate the efﬁ  cacy and safety of two maintenance 
regimens (8 weeks calcipotrol cream applied once daily 
or calcipotriol cream weekdays/two-compound ointment 
weekends) compared with vehicle, after 4 weeks’ acute treat-
ment of calcipotriol/betamethasone dipropionate (White et al 
2006). The group of patients which used the two-compound 
ointment on weekends during the maintenance period had a 
greater reduction in PASI (58.4%), than calcipotriol (44.5%) 
and vehicle (33.1%) at week 12.
Finally, to investigate the long term safety (Kragballe 
et al 2006a) and efﬁ  cacy (Kragballe et al 2006b) of the 
two-compound ointment, a randomized, double-blind, 
52-week, study was performed. In this double-blind study, 
634 patients were randomized with once-daily (when 
required) treatment with either: 52 weeks of two-compound 
product (n = 212), 52 weeks of alternating 4-week periods of 
two-compound product and calcipotriol (n = 213), or 4 weeks 
of two-compound product followed by 48 weeks of calcipotriol 
(n = 209). Disease severity at baseline was moderate in 69.1% 
of patients, severe in 27.9%, and very severe in 3.0%. The 
median duration of psoriasis was 17.0 years and the mean age 
of patients was 48.8 years. Although long-term safety was 
the primary objective of the study, efﬁ  cacy results were also 
presented. At the end of this study, more patients treated with 
calcipotriol/betamethasone dipropionate for 52 weeks had 
“satisfactory” responses to treatment as determined by the 
Investigators’ Global Assessment compared with patients who 
received alternating two-compound product and calcipotriol, 
or two-compound product for 4 weeks and calcipotriol for 48 
weeks, although this difference was not signiﬁ  cant (p = 0.071) 
(Kragballe et al 2006b), as the study was not designed to 
determine efﬁ  cacy (Kragballe et al 2006b). In the alternating 
group, the proportion of satisfactory responses after a 
calcipotriol/betamethasone dipropionate treatment period 
was always higher than that after a calcipotriol treatment 
period. These results provide evidence that the two-compound 
ointment used intermittently, as needed for 52 weeks, showed 
no sign of tachypylaxis and effectively controlled psoriasis 
(Kragballe et al 2006b).
Safety and tolerability
The two-compound ointment with calcipotriol/betametha-
sone dipropionate is safe and well-tolerated for the treatment 
of psoriasis vulgaris, as has been shown by the clinical 
trials mentioned above (Douglas et al 2002; Guenther et al 
2002; Kaufmann et al 2002; Papp et al 2003; Kragballe 
et al 2004; Ortonne et al 2004). The most common adverse 
drug reactions were those related to irritation of the skin 
(lesional/perilesional, pruritus, burning, erythema) (Guenther 
et al 2002; Kaufmann et al 2002; Papp et al 2003) and 
appeared in 2.6% of once-daily calcipotriol/betamethasone 
dipropionate recipients or 4.9%–5.1% of twice daily 
calcipotriol/betamethasone dipropionate recipients. Skin 
atrophy was noted in one recipient of the two-compound 
ointment in each of the three trials.
The only serious, possibly drug-related, adverse event 
reported was facial edema in a patient with widespread, 
oozing, crusting psoriasis after 2 weeks’ treatment with the 
two-compound ointment twice-daily, which was resolved after 
the discontinuation of the product (Douglas et al 2002).
The adverse events associated with long-term topical 
corticosteroid use in the 52-week safety study were recorded 
by the investigators and were adjudicated by an independent 
panel of 3 dermatologists who were blinded to the treatments Therapeutics and Clinical Risk Management 2008:4(1) 145
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(Kragballe et al 2006a). There were 10 patients (4.8%) with 
11 adjudicated corticosteroid-related adverse events in the 
two-compound ointment group, 6 patients (2.8%) with 7 
events in the alternating group, and 6 patients (2.9%) with 6 
such events in the two-compound ointment 4 weeks/calci-
potriol 48 weeks group. Median time to onset of an adverse 
event was 13, 25, and 20 weeks, respectively.
There were no statistically signiﬁ  cant differences between 
treatment groups. One of the major concerns of long-term 
topical corticosteroid use, the incidence of skin atrophy, was 
low in all groups:
•  In the group that received the two-compound ointment for 
4 weeks and then calcipotriol for 48 weeks, skin atrophy 
was observed in 2 patients, even though they received 
very little topical corticosteroid over the course of the 
study. Furthermore, in both cases, the skin atrophy was 
reported rather late during the clinical study, when the two 
patients were under calcipotriol treatment. Other adverse 
events were: adrenal insufﬁ  ciency, which was observed 
toward the end of the treatment period (week 52) in 1 
patient which was possibly unrelated to the use of the 
study treatment, cellulitis, hypertrichosis, and purpura 
(each in one patient)
•  One case of skin atrophy was observed in the alternating 
two-compound ointment/calcipotriol regimen. Folliculitis, 
pustular rash, skin papilloma, strie (each in one patient), 
and furuncles (two patients) were also reported.
•  Four cases of skin atrophy were noted in patients receiv-
ing the two-compound ointment for the entire period 
and after 10 to 33 weeks in the study. In 3 patients the 
atrophy resolved. Other adverse events were folliculitis 
(three patients), skin depigmentation (two patients), 
ecchymosis, and purpura (each in one patient).
No signiﬁ  cant changes in serum calcium were reported in 
these clinical trials (Guenther 2005), systematic absorption 
is minimal (Guenther 2005), and the number of lesional/per-
ilesional adverse drug reactions for patients  60years of age 
and those  60 years was similar (6.4% vs 5.0%) (Parslew 
and Traulsen 2005).
The better tolerability of the two-compound ointment is 
thought to be due to the anti-inﬂ  ammatory effect of betametha-
sone. The corticosteroid in the two-compound ointment seems 
to minimize the adverse events (irritation) of calcipotriol.
Dosage and administration
Calcipotriol 50 µg/g plus betamethasone dipropionate 0.5 
mg/g ointment is indicated for the topical treatment of stable 
plaque psoriasis vulgaris in adults 18 years of age and above. 
The recommended treatment period is 4 weeks. After this 
period, repeated treatment with the two-compound product 
can be initiated under medical supervision according to the 
new product label. It should be applied once daily on  30% 
of the body surface. The maximum dose should not exceed 
15 g/day and 100 g/week. The two-compound product 
should not be applied to the face, axillae, groin, or thin skin 
areas (van de Kerkhof et al 2006) and is contraindicated 1) 
in those patients with a history of hypersensitivity to any 
of the components, 2) in patients with disorders of calcium 
metabolism, and 3) in patients with erythrodermic, exfolia-
tive, and pustular psoriasis.
Pharmacoeconomic analyses
Calcipotriol/betamethasone dipropionate ointment applied 
once-daily is more effective and less costly than tacalcitol or 
calcipotriol for treating psoriasis (Fenton and Plosker 2004; 
Peeters et al 2005; Charakida et al 2006).
Conclusion
The two-compound ointment with calcipotriol 50 µg/g and 
betamethasone dipropionate 0.5 mg/g is a convenient, very 
effective, safe, and well tolerated therapy for psoriasis. The 
percentage of patients with a satisfactory response is higher 
with the two-compound ointment than with other topical 
treatments used in the past. Patients also are satisﬁ  ed by the 
treatment, their clinical condition improves quickly, and sig-
niﬁ  cant results are seen in 1 week. This aids compliance. It is 
well known that lack of efﬁ  cacy can have a negative effect on 
compliance as indicated by a recent ﬁ  nding that up to 40% of 
patients were intentionally noncompliant with their therapy 
because they believed the treatment took too long to have an 
effect (Peeters et al 2005). The two-compound ointment with 
its rapid onset of action and sustained efﬁ  cacy can quickly 
clear resistant lesions such as those on the elbows, knees, 
and legs, thus motivating patients to maintain compliance 
with their therapy (Carroll et al 2004; Antsey and Kragballe 
2006). Another issue that may enhance compliance is the 
simple once-daily application.
Treatment efﬁ  cacy, due to the synergistic clinical effect of 
two widely used compounds, provides a strong improvement 
of patients’ PASI irrespective of the severity of psoriasis. In 
clinical trials, patients with a mean baseline PASI of 9.5–10.9 
experienced a mean 65.0%–74.4% PASI improvement within 
4 weeks. In addition, in 6.1%–20.1% of patients, lesions 
cleared. Today the two-compound ointment is the most 
effective topical treatment for psoriasis vulgaris, which is 
currently available (Charakida et al 2006). Certainly there Therapeutics and Clinical Risk Management 2008:4(1) 146
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are some patients who fail to respond to the treatment for a 
reason which remains unclear.
Recent studies provide good evidence that the two-
compound ointment is safe and well-tolerated in repetitive use 
as required over a longer period of time for up to 52 weeks. 
Pooled safety data from 7 clinical studies proved that the two-
compound ointment is safe, with side effects mainly involving 
local skin reactions of mild intensity (Papp and Melgaard 
2007). The proportion of patients with adverse drug reactions 
was smaller with the two-compound ointment and there was 
no increase in corticosteroid-related adverse events.
The two-compound ointment with calcipotriol 50 µg/g 
and betamethasone dipropionate 0.5 mg/g should be seen 
as the ﬁ  rst-line treatment of choice for psoriasis vulgaris 
amenable to topical treatment (Charakida et al 2006) and 
should be used acutely for 4–8 weeks to bring psoriasis under 
control. After this, control of the disease can be maintained 
either 1) with calcipotriol monotherapy on weekdays and 
two-compound ointment on weekends or three-times a week 
(Monday/Wednesday/Friday) (Guenther 2005) or 2) with the 
two-compound ointment once-daily as needed (Figure 1). 
The latter treatment recommendation would possibly enhance 
patient adherence to treatment as it does not involve two 
different medications and provides an opportunity for indi-
vidualized treatment regimen.
Psoriasis is a chronic disease and usually requires long-
term treatment with optimal safety. Approximately 70%–80% 
of all patients with psoriasis can be managed adequately with 
use of topical therapy alone (Sterry et al 2004; Schön and 
Boehncke 2005). In conclusion, the two-compound ointment 
should be considered as the initial therapeutic approach for 
psoriasis vulgaris or as an adjunctive therapy in patients 
on systemic agents (acitretin, methotrexate, cyclosporine, 
biologics) or phototherapy (Rogers 2006).
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